Building an Integrated Platform through the Consortium for Developing the Value Chain for Large-Scale Cell Manufacturing
First written in FY2025-H1. 5 of 7 entries say "Advanced", first in 2026-05-15. Latest entry: 2026-08-21.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As of the end of March 2026, we were conducting development activities with 14 members. Based on the elemental technologies developed with the participating companies, we will install a pilot-scale plant.」
The number of VMaCS members reached 14, and the company moved to the stage of installing a pilot-scale plant based on the development of elemental technologies. - FY2025-H1First statedAnnual report
「The Group is participating in this consortium with manufacturing and quality-control technologies for iPS cell-derived regenerative medical products and proprietary design technologies for cell-culture processing facilities capable of mass production. Together with the participating companies, we will be among the first in the world to develop a platform system integrating the processes of culturing, harvesting, filling and dispensing, freezing and storage that constitute mass production of cells, as well as applications used in this system.」
At Nakanoshima Qross, the company began developing a mass-production platform and applications integrating processes from cell culture through storage. The company plans to use the results in its own business and as a packaged system in Japan and overseas.